NIH Starts Study On Allergic Reactions Risk To Pfizer/BioNTech, Moderna COVID-19 Vaccines

The National Institutes of Health (NIH) has begun a mid-stage study to determine the risk of allergic reactions shortly after receiving COVID-19 vaccines made by Moderna Inc MRNA and Pfizer Inc PFE/BioNTech SE BNTX.
Several allergic reaction incidents, including serious episodes known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.
“The information gathered during this trial will help doctors advise people who are highly allergic or have a mast cell disorder about the risks and benefits of receiving these two vaccines. However, for most people, the benefits of COVID-19 vaccination far outweigh the risks,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID).
The NIH Phase 2 study will enroll 3,400 adults ages 18 to 69. Participants will be randomly assigned to receive either a Pfizer-BioNTech vaccine, a Moderna vaccine, a placebo followed by a Pfizer-BioNTech vaccine, or a placebo followed by the Moderna vaccine.
The trial’s goal is to assess the proportion of participants with a systemic allergic reaction within 90 minutes after injection. Data is expected to be reported later this summer.
An independent data and safety monitoring board (DSMB) will review blinded and unblinded study data at scheduled review meetings to ensure study participants’ safety.
Price Action: PFE, BNTX, and MRNA shares are down 0.36% at $35.92, 3.82% at $112.68, and 1.21% at $131.92, respectively, during market trading hours on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga